CNS Pharmaceuticals (CNSP) vs MetaVia (MTVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MetaVia is the larger company by market cap ($9.2 million vs $7.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSP | MTVA |
|---|---|---|
| Share price | $5.34 | $1.40 |
| Market cap | $7.80M | $9.22M |
| 1-day change | -0.19% | +4.48% |
| EPS (TTM) | $-17.90 | $-3.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.54 | $14.85 |
| 52-week low | $1.90 | $0.966 |
| Distance from 52-week high | -49.34% | -90.57% |
| Analyst consensus | none | none |
| Avg. price target upside | +87.27% | +1280.71% |
| Average volume | 6.40K | 228.48K |
| Shares outstanding | 1.46M | 6.59M |
| Employees | 8 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About MetaVia
MTVA stock →MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
CNSP vs MTVA FAQ
Which is bigger, CNS Pharmaceuticals or MetaVia?
MetaVia (MTVA) is larger, with a market capitalization of $9.22M compared with $7.80M for CNS Pharmaceuticals (CNSP).
Are CNS Pharmaceuticals and MetaVia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.